JP2017507142A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507142A5
JP2017507142A5 JP2016553284A JP2016553284A JP2017507142A5 JP 2017507142 A5 JP2017507142 A5 JP 2017507142A5 JP 2016553284 A JP2016553284 A JP 2016553284A JP 2016553284 A JP2016553284 A JP 2016553284A JP 2017507142 A5 JP2017507142 A5 JP 2017507142A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
fgf
cartilage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553284A
Other languages
English (en)
Japanese (ja)
Other versions
JP6431082B2 (ja
JP2017507142A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053631 external-priority patent/WO2015124731A1/en
Publication of JP2017507142A publication Critical patent/JP2017507142A/ja
Publication of JP2017507142A5 publication Critical patent/JP2017507142A5/ja
Application granted granted Critical
Publication of JP6431082B2 publication Critical patent/JP6431082B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553284A 2014-02-20 2015-02-20 Fgf−18化合物の投与計画 Active JP6431082B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
EP14000600.8 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
JP2017507142A JP2017507142A (ja) 2017-03-16
JP2017507142A5 true JP2017507142A5 (enExample) 2018-03-01
JP6431082B2 JP6431082B2 (ja) 2018-11-28

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Country Status (25)

Country Link
US (2) US9724388B2 (enExample)
EP (2) EP3119417B1 (enExample)
JP (2) JP6431083B2 (enExample)
KR (2) KR102410986B1 (enExample)
CN (2) CN106232622A (enExample)
AR (2) AR099510A1 (enExample)
AU (2) AU2015220773B2 (enExample)
BR (2) BR112016018685A2 (enExample)
CA (1) CA2938791A1 (enExample)
DK (2) DK3107559T3 (enExample)
ES (2) ES2689071T3 (enExample)
HR (2) HRP20181570T1 (enExample)
HU (1) HUE040350T2 (enExample)
IL (2) IL247083B (enExample)
LT (2) LT3107559T (enExample)
MX (2) MX2016010871A (enExample)
NZ (1) NZ723148A (enExample)
PL (2) PL3107559T3 (enExample)
PT (2) PT3119417T (enExample)
RS (2) RS57709B1 (enExample)
RU (2) RU2700582C2 (enExample)
SG (2) SG11201606502YA (enExample)
SI (2) SI3107559T1 (enExample)
WO (2) WO2015124727A1 (enExample)
ZA (2) ZA201605548B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) * 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
JP7671249B2 (ja) * 2019-02-08 2025-05-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 変形性関節症が急速に進行するリスクがある患者の治療
KR102920449B1 (ko) * 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
CN122161846A (zh) * 2023-10-11 2026-06-05 四川至善唯新生物科技有限公司 治疗关节炎的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551426B1 (en) * 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2006014444A1 (en) * 2004-07-06 2006-02-09 Zymogenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
NZ574216A (en) * 2006-08-25 2011-11-25 Ares Trading Sa Treatment of cartilage disorders with fgf-18
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
AU2012232658B2 (en) * 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18

Similar Documents

Publication Publication Date Title
JP2017512194A5 (enExample)
JP2012193216A5 (enExample)
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2015517488A5 (enExample)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
JP2015057451A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX2018008021A (es) Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
JP2013231087A5 (enExample)
JP2015038135A5 (enExample)
RU2016137289A (ru) Схема применения соединения fgf-18
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2017503014A5 (enExample)
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
JP2016539125A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2013541583A5 (enExample)
JP2016530291A5 (enExample)
JP2016512247A5 (enExample)
JP2015522603A5 (enExample)
JP2017507145A5 (enExample)
JP2017061488A5 (enExample)
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice
EP4474012A3 (en) Melatonin mini-tablets and method of manufacturing the same
JP2017531042A5 (enExample)